Mobile

ASUS: Abatacept in Seronegative Undifferentiated arthritis Study Prospective, Single-centre, Pilot Study Assessing the Efficacy of Abatacept in Anti-CCP Negative Undifferentiated Inflammatory Arthriti...

Update Il y a 5 ans
Reference: EUCTR2008-004878-41

ASUS: Abatacept in Seronegative Undifferentiated arthritis Study Prospective, Single-centre, Pilot Study Assessing the Efficacy of Abatacept in Anti-CCP Negative Undifferentiated Inflammatory Arthritis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the proportion of subjects with CCP-negative, power Doppler positive Undifferentiated Arthritis who on open-label Abatacept medication achieve the following criteria at 6 months: 1. DAS44 remission i.e. DAS44-CRP < 1.6 2. Maximum of one swollen joint for at least 3 consecutive months 3. No radiographic progression defined as change that does not exceed the smallest detectable change over one year

Inclusion criteria

  • Undifferentiated Arthritis

Links